Jeffrey S. Glenn - Mar 11, 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
Director
Signature
/s/ Sriram Ryali, Attorney-in-Fact
Stock symbol
EIGR
Transactions as of
Mar 11, 2022
Transactions value $
$0
Form type
4
Date filed
3/11/2022, 08:06 PM
Next filing
Dec 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EIGR Common Stock Award $0 +6K +7.86% $0.00 82.4K Mar 11, 2022 Direct F1
holding EIGR Common Stock 5K Mar 11, 2022 By spouse
holding EIGR Common Stock 460 Mar 11, 2022 By son
holding EIGR Common Stock 151K Mar 11, 2022 By Eiger Group International, Inc. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +12K $0.00 12K Mar 11, 2022 Common Stock 12K $5.10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying Restricted Stock Units award that will vest on the first anniversary of the grant date of March 11, 2022.
F2 Shares are held by Eiger Group International, Inc. ("EGI"). The Reporting Person is the Chief Executive Officer of EGI and has sole power to vote and sole power to dispose of shares directly owned by EGI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F3 The option vests in equal monthly installments over 12 months measured from March 11, 2022 subject to Reporting Person's continuous service status as of each such date.